FDBusiness.com

Biotech Company Nuritas Discovers New MRSA Killing Peptide

 Breaking News
  • Lactalis Expands in Infant Nutrition With €740 Million Acquisition Lactalis Group, the international dairy group based in Laval, France, is acquiring the Nutritional business of Aspen Pharmacare for €739.8 million (R12.9 billion). The business being acquired supplies a wide range of infant nutritional and growing-up milk products across both the premium and value segments. It manufactures and markets well established quality brands, including S-26, [...]...
  • Thatchers Cider to Invest £14 Million in New Cider Mill Thatchers Cider, the family owned English cider producer, is to invest £14 million in a new cider mill at its Myrtle Farm site in Somerset to meet growing demand for its products. The company has applied for planning permission and, if granted, the new mill would come on stream in 2019. “This investment is about our [...]...
  • Coca-Cola Great Britain Teams Up With Premier League Premier League and Coca-Cola Great Britain have announced a new three-and-a-half-year partnership, starting in January 2019. It is the first sponsorship Coca-Cola Great Britain will activate across multiple brands within its portfolio, showcasing a range of drinks including sparkling soft drinks, water and fruit-based drinks, with low and no-sugar options. The partnership will see Coca-Cola work [...]...
  • Barry Callebaut Completes $30 Million Capacity Expansion in North America Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa products, has announced the completion of several expansion investments in three of its North American facilities located in St Hyacinthe, Quebec; Chatham, Ontario; and St Albans, Vermont. The investments amount to close to US$30 million and are in line with previously announced plans. Recent investments [...]...
  • Strong First Half From Hilton Food Group Hilton Food Group, the UK-based leading specialist international food packing business, has reported a 25.0% increase in turnover to £863.6 million and by 24.5% on a constant currency basis for the 28 weeks to 15 July 2018. Volumes increased by 12.7% reflecting growth in the UK, Ireland and Australia. Operating profit for the first half [...]...

Biotech Company Nuritas Discovers New MRSA Killing Peptide

December 06
15:42 2014

Nuritas PhotoIrish bioinformatics company, Nuritas, today announced that it has discovered an MRSA killing peptide. The peptide, which is derived from a food by-product, is anticipated to provide a natural, healthy innovation in the fight against antibiotic resistant infections in both humans and animals.

Nuritas’ ground-breaking biotechnology is capable of quickly and cost-effectively harvesting ingredients which then may be developed and supplied to humans and animal producers for many different applications from topical applications to effective cleaning biocides.

Dr. Nora Khaldi, CEO of Nuritas, states “Our aim is to make ingredients that are more accessible, natural and meeting serious societal health needs.”

Unlike existing MRSA killing products, Nuritas has found a way to rapidly and effectively extract and activate safe and healthy antimicrobial molecules in food that are often overlooked. This is a world first in that most molecules are usually derived from non-sustainable sources that have unknown side effects on human health and cost millions and years to develop.

Dr. Marta Martins, Biotechnology Research Fellow at University College Dublin said that “The increase of antibiotic resistance in bacteria of clinical relevance is a major issue for Public Health and there is the immediate need for alternative solutions”. Nuritas’ announcement today of the discovery of an effective and natural peptide to combat MRSA comes at a crucial point in the MRSA battle it seems.

Staphylococcus aureus is a bacterium commonly found in the nose and/or skin of healthy persons and animals. Strains of this bacterium that are resistant to beta-lactam antibiotics are called Methicillin-Resistant Staphylococcus aureus (MRSA). If this bacterium penetrates the skin and enters the blood stream it can cause life-threatening infections due to its resistance to many of the currently used antibiotics.

The inappropriate use of antibiotics in human treatments and animal production is contributing to antibiotic resistance, allowing bacterium such as Staphylococcus aureus to continue to evolve. Developing treatments to keep up with the evolution of the bacterium are costly and time-consuming. Severe side effects are also associated with some of the second or last-line antibiotic treatments. Nuritas’ ingredients are cost-effectively and quickly mined from food sources eliminating the possible severe side effects associated with current therapies and uses.

Overall, Nuritas’ discovery has the potential to provide innovative treatment of the costly and dangerous MRSA causing-infections by providing affordable, healthy, sustainable anti-microbials to ensure the healthy, long life of humans and animals.

 

About Nuritas

downloadNuritas is a biotechnology company that radically changes the way we discover natural peptides that target key receptors to actively promote and manage health. The company uses artificial intelligence to data mine food, allowing the discovery of life-changing ingredients that can be added to personal care products, supplements, food or biocides. Nuritas is committed to applying its scientific expertise to translate nature into healthy, sustainable and cost-effective living for all.

About Author

colin

colin

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • September 25, 2018PPMA Show 2018
  • September 27, 2018Int'l Fruit Show (eurofruit)
  • September 30, 2018Trade Fair for Butchers, Caterers and Meat Industry (Meat Expo)
  • October 1, 2018Poznan International Fair
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber





Subscribe Here



Advertisements